Navigation Links
Astellas to Review Strategic Business Alternatives for Prosidion Subsidiary
Date:1/10/2011

obal category leader in urology, immunology & infectious diseases, neuroscience, DM complications & metabolic diseases and oncology. For more information on Astellas Pharma Inc., please visit our website at http://www.astellas.com/en.

About Prosidion

Prosidion Ltd. (a subsidiary of Astellas Pharma Inc.) is a biopharmaceutical company, focused on discovering, developing and commercializing innovative molecular targeted therapies addressing major unmet medical needs in type 2 diabetes and obesity. The company's biological research is focused on neuroendocrine control of body weight and glycaemia. This combined with special expertise in the area of designed multiple ligands is geared to deliver novel, innovative first- or best-in-class therapies for type 2 diabetes and obesity. Prosidion is located in Oxford, in the UK close to a seat of international academic excellence. The company has state of the art facilities and fully integrated capabilities in research and development.

Statement of Cautionary Factors

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new us
'/>"/>

SOURCE Astellas Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reportlinker Adds Astellas Pharma Inc.: PharmaVitae Profile
2. Astellas Announces Retirement of Donald Rice and Appointment of Sef Kurstjens as CEO and President of Agensys, Inc.
3. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
4. Astellas Mobilizes 1,300+ Employees in the Americas to Participate in First Annual Changing Tomorrow Day
5. Astellas Awards Scholarships to 12 Transplant Recipients and Donors Who Embody Hope, Courage and Achievement
6. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
7. Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period
8. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
9. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
10. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
11. Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  Northstar Global ... Depository Trust Company (DTC) has made their final ... Chill on the Company,s stock effective December 15, ... common stock for depository and book entry transfer ... Company is now once again fully "DTC Eligible", ...
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, Inc. ... music products, today announced that it has signed ... manufacturer and supplier of innovative prosthetic, orthotic and ... part of the agreement, RSL Steeper will promote ... specifically configured for use within UK residential care ...
(Date:12/17/2014)... LOS ANGELES , Dec. 17, 2014 /PRNewswire/ ... that the US Patent and Trademark Office (USPTO) ... candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting ... glioblastoma. The claims of US Patent No. 8,871,211, ... treating neural cancer by administering a dendritic cell ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... Inc. (NYSE: LDR ), a recognized leader ... and high quality medical consumable accessories, today reported financial results ... Fiscal 2012 Second Quarter Highlights ... prior year period. , Gross profit grew 11 percent ...
... Inc. (NASDAQ: UPI ), a medical device ... for the treatment of voiding dysfunctions, announced today that ... President and CFO, will present the Company,s business strategy ... JMP Securities Research Conference at 12:30 pm PT on Monday, ...
Cached Medicine Technology:Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 2Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 3Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 4Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 5Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 6Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 7Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 8Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 9Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 10Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 11Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 12Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 13Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 14Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 15Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 16Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 17Uroplasty to Present at the 11th Annual JMP Securities Research Conference 2
(Date:12/21/2014)... December 21, 2014 When families in Coral ... do they call? The new answer is Lice Troopers ... FL 33134, their newest treatment center will be the new ... conveniently and without the use of harmful chemicals or pesticides. ... for January 1, 2015. Like the company’s first clinic (located ...
(Date:12/21/2014)... New York, New York (PRWEB) December 21, 2014 ... http://www.byettalawsuit2013.com/ ) and other product liability claims involving ... as incretin mimetics continue to move forward in ... District Court, Southern District of California, Bernstein Liebhard ... 17th, the Court has established a data cut-off ...
(Date:12/21/2014)... Recently, one of the best prom ... Shop has introduced its new collection of 2015 ... discounts on all its prom dresses & other fashionable ... on providing top quality dress products and great customer ... as one of the best prom dresses online shops ...
(Date:12/21/2014)... Muskegon, Mi (PRWEB) December 21, 2014 ... a child in need while at the same time helping ... is a non-profit community-based organization committed to serving those ... to meet their needs to improve the quality of life. ... would make an impact in the local community and he ...
(Date:12/21/2014)... 21, 2014 Parker & Sons, Inc. ... cooling, plumbing and other similar home contractor services announces ... regard to its expert contracting services. The company is ... has been serving Arizona for well over 40 years. ... absolute best in quality customer service to the residents ...
Breaking Medicine News(10 mins):Health News:All-Natural Florida Lice Removal Company Opens New Lice Treatment Salon In South Florida 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:New Prom Dresses From One Of The Best Prom Dresses Online Shops, LunaDress Prom Shop 2Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3
... Thursday 11 June 2009: DNA vaccination using lupus autoantigens ... role in regulating the immune system) has potential as ... may help to prevent kidney damage in patients with ... presented today at EULAR 2009, the Annual Congress of ...
... Insurer Hires 200th Employee , , Momentum Builds for ... Care Insurance Crisis , , AVENTURA, Fla., June 11 ... insurance benefit programs for the consumer market, today announced the ... Health is a company with a clear mission -- to ...
... As Congress prepares to debate a major overhaul of ... in support of several proposals to expand coverage that have ... annual Health Confidence Survey released today. But attitudes could change ... , Between 68 percent and 88 percent of Americans ...
... and lecturer lends his expertise to special ed school ... Montgomery Academy,s Board of Trustees voted unanimously during its May ... of the nonprofit, state approved school. , , ... serves as both its Chief Executive Officer and Chief Scientific ...
... and Developments at Boston Hyatt Harborside June 11-12 ... today, the Games for Health Project ( www.gamesforhealth.org ) ... Boston Hyatt Harborside. Having grown more than 300 percent since its initial ... sharpest minds in the game development and health fields to explore the ...
... SmallCapSentinel.com has issued a Market Actives List for Thursday, ... trading activity for Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ... roughly 14 times average daily volume Wednesday, Citigroup Inc. (NYSE: ... SAY ), Google Inc. (Nasdaq: GOOG ), ...
Cached Medicine News:Health News:Novel DNA vaccine leads to kidney damage prevention in systemic lupus erythematosus models 2Health News:Cinergy Health Expands Staff in Face of Dramatic Growth 2Health News:12th Annual Health Confidence Survey: Americans Show Support for Several Health Coverage Options, But Their Views Could Change as More Details Emerge 2Health News:12th Annual Health Confidence Survey: Americans Show Support for Several Health Coverage Options, But Their Views Could Change as More Details Emerge 3Health News:Dr. Philip A. DeFina of International Brain Research Foundation Joins Montgomery Academy Board of Trustees 2Health News:Fifth Annual Games for Health Conference Kicks Off in Boston 2Health News:Fifth Annual Games for Health Conference Kicks Off in Boston 3Health News:Fifth Annual Games for Health Conference Kicks Off in Boston 4Health News:SmallCapSentinel.com Releases Market Actives List for JAZZ, MEXP, C, SAY, GOOG, AAPL 2
... High Density, multi-frequency, linear flexible ... on the UST-5536, this "Omni-Plane ... sweeps horizontally as well as ... so that target lesions can ...
Super High Density, multi-frequency, end-fire phased array transducer. Point-and-shoot scanning is the benefit of this transducer....
This is a 3D transducer for endovaginal imaging in OB/GYN....
This is a 3D transducer for endovaginal imaging in OB/GYN....
Medicine Products: